The Preoperative Assessment and Optimization of Patients Undergoing Major Urological Surgery.

PURPOSE OF REVIEW: Improving patient outcomes from major urological surgery requires not only advancement in surgical technique and technology, but also the practice of patient-centered, multidisciplinary, and integrated medical care of these patients from the moment of contemplation of surgery until full recovery. This review examines the evidence for recent developments in preoperative assessment and optimization that is of relevance to major urological surgery. RECENT FINDINGS: Current perioperative medicine recommendations aim to improve the short-term safety and long-term effectiveness of surgical treatments by the delivery of multidisciplinary integrated medical care. New strategies to deliver this aim include preoperative risk stratification using a frailty index and cardiopulmonary exercise testing for patients undergoing intra-abdominal surgery (including radical cystectomy), preoperative management of iron deficiency and anemia, and preoperative exercise intervention. Proof of the utility and validity for improving surgical outcomes through advances in preoperative care is still evolving. Evidence-based developments in this field are likely to benefit patients undergoing major urological surgery, but further research targeted at high-risk patients undergoing specific urological operations is required.

Assessment of zinc deficiency and effect of dietary carrot, amchur and onion on zinc status during repletion in zinc-deficient rats.

BACKGROUND: Food acidulants, ß-carotene-rich vegetables and sulfur compound-rich Allium spices are known to improve zinc bioaccessibility from food grains. This animal study evaluated the positive influence of these promoters of zinc bioaccessibility on zinc status during zinc repletion in Wistar rats previously rendered zinc-deficient by feeding a zinc-deficient semi-synthetic diet for 4 weeks. Groups of these zinc-deficient animals were subsequently maintained on a zinc-containing grain-based diet for 2 weeks. Various experimental diets consisted of the grain-based diet supplemented with (1) carrot, (2) onion, (3) amchur, (4) carrot + amchur and (5) onion + amchur. RESULTS: Zinc deficiency was confirmed by lower zinc concentration in tissues and bones and lower activity of zinc-containing enzymes. Zinc concentration was 10-15% lower in serum, liver and kidney of zinc-deficient rats. Bone weight in zinc-deficient rats was 20% lower than that in normal rats. Activities of zinc-containing enzymes (hepatic superoxide dismutase and alcohol dehydrogenase and serum alkaline phosphatase) were lower in the zinc-deficient group. Animals fed diets supplemented with these promoters of zinc bioaccessibility showed better zinc status in tissues and bones compared with those repleted with the control stock diet. CONCLUSION: This animal study supports the claim of promoters of zinc bioaccessibility for improving zinc status, which may find practical application.

SHOX mutation as a rare disease: molecular diagnosis and growth hormone treatment supported by the Italian public health system.

Short stature homeobox-containing (SHOX) gene deficiency is acknowledged under the term "dyschondrosteosis", which is included in the family of congenital osteodystrophies. Under current regulations, the cost of the genetic testing and treatment with GH in children with short stature, and SHOX gene deficiency may be reimbursed. Prescription of costs exemption is subject to the identification of the regional centers qualified to diagnose congenital osteodystrophies (RNG060). The centers qualified to diagnose and treat "dyschondrosteosis" have been identified in only a few regions, whereas in other regions centers for the diagnosis and treatment of congenital osteodystrophies have been identified, and in still others, no specific centers have been identified yet. Treatment with GH as indicated by European Medicines Agency (EMEA) for people with short stature and evidence of SHOX gene deficiency is governed by Agenzia Italiana del Farmaco (AIFA) note number 39. The latest version does not provide for the medication to be directly reimbursed by the National Health Service, although it may be prescribed for patients with well-defined auxological characteristics, subject to the prior authorization of the regional commission qualified to monitor the use of the GH. Therefore, a diagnostic/ therapeutic course for patients with short stature with SHOX gene mutation has been proposed. The healthcare course relating to such patients has not been thoroughly defined in terms of implementation and is affected by regional organizational approaches. Implementing specific healthcare courses for such patients may provide a model for treating other patients with short stature and rare diseases with GH.

Mecasermin: new drug. Insufficient improvement in statural growth.

(1) Human insulin-like growth factor type 1 (IGF-1) is the main effector of growth hormone action. Primary IGF-1 deficiency is a rare disease, mainly resulting in very short stature; (2) Mecasermin is a recombinant IGF-1 marketed for this indication as a twice daily subcutaneous injection; (3) Clinical evaluation is mainly based on a non-comparative follow-up study of 76 children with an average age of 7 years, some of whom were treated for 8 years. The mean height at treatment initiation was 6.7 standard deviations below normal. Eight years later, it was 5.2 standard deviations below normal, i.e. their growth failure remained very severe; (4) The main short-term adverse effects of mecasermin are hypoglycaemia, headache and intracranial hypertension. Nearly one in 5 children developed tonsillar hypertrophy, resulting in otitis and hypoacusis; (5) Animal studies showed hypertrophy of other organs (kidneys, spleen and heart) as well as carcinogenic effects. The risk in humans is unknown; (6) The mecasermin packaging is not well-adapted (a multidose vial designed to be punctured several times), and is a potential source of contamination and errors. Prefilled pens or syringes would be easier to use; (7) In practice, the limited clinical benefits of mecasermin do not justify exposure to its potential risks.

Effects of bovine serum concentrate, with or without supplemental micronutrients, on the growth, morbidity, and micronutrient status of young children in a low-income, peri-urban Guatemalan community.

OBJECTIVE: To determine the effects of dietary supplements containing bovine serum concentrate (BSC, a source of immunoglobulins) and/or multiple micronutrients (MMN) on children's growth velocity, rates of common infections, and MN status. DESIGN: Randomized, controlled, community-based intervention trial. SETTING: Low-income, peri-urban Guatemalan community. SUBJECTS: Children aged 6-7 months initially. INTERVENTIONS: Children received one of four maize-based dietary supplements daily for 8 months, containing: (1) BSC, (2) whey protein concentrate (WPC, control group), (3) WPC+MMN, or (4) BSC+MMN. RESULTS: There were no significant differences in growth or rates of morbidity by treatment group. Children who received MMN had lower rates of anemia and (in the group that received WPC+MMN) less of a decline in serum ferritin than those who did not, but there were no differences in other biochemical indicators of MN status by treatment group. CONCLUSIONS: MMN supplementation reduced anemia and iron deficiency in this population, but the MMN content and source of protein in the supplements did not affect other indicators of MN status, growth or morbidity.

Nutritional supplements in pregnancy: commercial push or evidence based?

PURPOSE OF REVIEW: This review examines whether nutritional supplements during pregnancy have a role to play in the health of the mother, outcome of pregnancy or health of the baby. It will put into context the increased use of nutritional supplements in pregnancy and whether there is an evidence base for this supplementation. RECENT FINDINGS: Women are not consuming enough nutrients from their diet alone and food is depleted in many important minerals. There is increasing support that supplementation of specific vitamins, minerals and omega-3 fatty acids can have a positive impact on maternal health in terms of prevention of preeclampsia, miscarriage, preterm birth, low birthweight, gestational diabetes and also on the long-term health of the baby. There are some contradictory findings with antioxidants and prevention of preeclampsia, and these are discussed. SUMMARY: With soil depletion, overfarming and transportation of foods over hundreds of miles with loss of nutrients en route, together with the increased use of convenience and fast foods, women can be over-fed, but under-nourished in our modern society. These can lead to nutrient deficiencies which can have an impact on the outcome of pregnancy. Evidence shows that supplementation can play a valuable role in the health of the pregnant mother and her baby. Emphasis must always be on eating a good diet, but given the limitations of the 21st century lifestyle and the nutritional content of food, good quality nutritional supplements should be used during pregnancy in combinations rather than isolated single nutrients.

Multiple micronutrient deficiencies: future research needs.

There has been a rising current of calls for a moratorium on international nutritional research in favor of an investment in intervention programs, per se. The topic of multiple-micronutrient supplementation reviewed at the International Workshop on Multi-Micronutrient Deficiency Control in the Life Cycle (May 30-June 1, 2001) has confirmed once again, however, the intimate interaction between program development and a supporting agenda of applied research. The areas of research required to produce successful intervention programs include biologic availability, safety and efficacy, communications and behavior, effectiveness, cost-effectiveness (efficiency), and food and pharmaceutical technology. Attention to safety and surveillance for unintended adverse effects has acquired new relevance as we analyze the multi-center International Research on Infant Supplementation (IRIS) I studies. All professionals involved in research projects in this area must assure both the quality and reliability of investigations and adhere to the highest principles of ethical conduct of research in human studies. The fundamental principles of research design and hypothesis development, quality assurance, reliability of measurements, and sound and unbiased interpretation of findings apply to all experimental science, and must be guaranteed for this mission. Agencies, academic institutions, and industry alike must work to create a system in which researchers can uphold these standards, and realize at the same time that the area of multi-micronutrient supplementation in developing countries can be a fertile area for training future researchers.

Oncotic pressure, albumin and ileus: the effect of albumin replacement on postoperative ileus.

The effect of decreased colloid oncotic pressure, as seen in hypoalbuminemia and hypoproteinemia, upon intestinal function has been well delineated in the surgical literature. Patients undergoing abdominal aortic aneurysm resection or aortoiliac or aortofemoral bypass grafts are almost uniformly hypoalbuminemic postoperatively; with these two facts in mind, a prospective, randomized clinical study was undertaken to identify the role of serum albumin concentration on the length of postoperative ileus in this population. The main hypothesis was that patients whose albumin levels dropped below 3.5 gm/dL would have a more prolonged postoperative hospital course as a result of delay in return of bowel function when compared with those patients in whom the low albumin levels were exogenously acutely replenished to > 3.5 gm/dL. Albumin was replaced to a level greater-than or equal to 3.5 g/dL in one group of 37 patients (AR), with a control group of 32 patients (NR) not receiving any albumin. Return of bowel function was measured by the postoperative day that flatus was documented, as well as the postoperative day oral intake was resumed. Mean values were determined for each group, and t tests did not reveal a significant difference in postoperative day of flatus (AR mean = 4.06 days, NR mean = 4.16 days) or postoperative day of oral intake (AR mean = 4.0, NR mean = 3.75). Additional comparisons between the groups involving the number of postoperative days until a regular diet was begun (AR mean = 6.06, NR mean = 5.48) and length of postoperative hospital stay (AR mean = 9.16, NR mean = 8.43) failed to reveal significant differences.(ABSTRACT TRUNCATED AT 250 WORDS)